30 November 2021: ReNeuron Group plc (AIM: RENE), a UK based leader in Stem Cell and Exosome Technologies, announces its interim results for the six months ended 30 September 2021.

Read more…

19 November 2021: ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, announces that new data relating to its CTX-derived induced Pluripotent Stem Cell (“CTX-iPSC”) platform has been presented this week, showing their commercial potential for the development of mass-scale therapeutics for peripheral nerve repair.

Read more…

18 November 2021: ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, will announce its interim results for the six months ended 30 September 2021 and business update on Tuesday 30 November 2021.

Read more…

ReNeuron collaborates with UCL to generate anti-cancer immune cells for cancer therapies

26 October 2021: ReNeuron Group plc (AIM: RENE), a global leader in the development of cell-based therapeutics, announces that it has entered a collaboration agreement with University College London (‘UCL’) to conduct research into the generation of immune cells from induced pluripotent stem cells (‘iPSCs’) for anti-cancer cell therapies. ReNeuron will be working alongside Dr Claire Roddie, Associate Professor, UCL Cancer Institute, and the team at the UCL CAR-T cell cancer therapy programme.

Read more…

Oxford University Hospitals NHS Foundation Trust activated as ReNeuron’s first UK study site

18 October 2021: ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, provides a further update on the progress of its Phase 2a clinical evaluations for the treatment of retinitis pigmentosa (‘RP’), an inherited, degenerative eye disease.

Read more…

18 October 2021: ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, provides an update on changes to the Company’s Board of Directors.

Read more…

Significantly improved delivery of functional proteins to the brain demonstrated in vivo

Exosomes have potential to transform effective drug delivery for key neurological diseases

11 October 2021: ReNeuron Group plc (AIM: RENE), a global leader in the development of exosome therapeutics, announces positive data that provides clear pre-clinical proof-of-concept that ReNeuron’s novel exosome drug delivery technology can effectively deliver therapeutic proteins to the specific region of the brain affected by several neurological diseases.

Read more…

01 October 2021: ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, provides an update on the Company’s Phase 2a clinical evaluations for the treatment of retinitis pigmentosa (‘RP’), an inherited, degenerative eye disease.

Read more…

ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, announces that at the Annual General Meeting (AGM) held earlier today, all resolutions were duly passed.

Read more…

06 August 2021: ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, announces the appointment of Catherine Isted, ACMA, who will be joining the Board as Chief Financial Officer effective 11 October 2021.

Read more…